- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Spexis AG (SPEXN)"Spexis AG stock price live, this page displays SIX SPEXN stock exchange data. View the SPEXN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Spexis AG real time stock price chart below.
What Is the Spexis AG Stock Price Today?
The Spexis AG stock price today is 0.02.
What Is the Stock Symbol for Spexis AG?
The stock symbol for Spexis AG is ""SPEXN.""
What Stock Exchange Does Spexis AG Trade On?
Spexis AG is listed and trades on the Switzerland stock exchange.
Is Spexis AG a Good Stock to Buy?
Determining whether Spexis AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPEXN quote. (ISIN: CH0106213793)"
What Is the Spexis AG Stock Price Today?
The Spexis AG stock price today is 0.02.
What Is the Stock Symbol for Spexis AG?
The stock symbol for Spexis AG is ""SPEXN.""
What Stock Exchange Does Spexis AG Trade On?
Spexis AG is listed and trades on the Switzerland stock exchange.
Is Spexis AG a Good Stock to Buy?
Determining whether Spexis AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPEXN quote. (ISIN: CH0106213793)"
0.02
0.00(0.00%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.02
0.02
52 wk Range
0.01
1.06
SPEXN Scorecard
Full Analysis
Operates with a significant debt burden
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.020.02
52 wk Range
0.011.06
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockSPEXN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Spexis AG Company Profile
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
Compare SPEXN to Peers and Sector
Metrics to compare | SPEXN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPEXNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −4.2x | −0.7x | |
PEG Ratio | −0.05 | −0.02 | 0.00 | |
Price/Book | 1.5x | 1.7x | 2.6x | |
Price / LTM Sales | 5.7x | 13.0x | 3.2x | |
Upside (Analyst Target) | - | 147.3% | 45.9% | |
Fair Value Upside | Unlock | 19.3% | 7.6% | Unlock |
FAQ
What Is the Spexis (SPEXN) Stock Price Today?
The Spexis stock price today is 0.02
What Stock Exchange Does Spexis Trade On?
Spexis is listed and trades on the Switzerland stock exchange.
What Is the Stock Symbol for Spexis?
The stock symbol for Spexis is "SPEXN."
What Is the Spexis Market Cap?
As of today, Spexis market cap is 1.35M.
What is Spexis Earnings Per Share?
The Spexis EPS is -0.37.
From a Technical Analysis Perspective, Is SPEXN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.